高级检索
当前位置: 首页 > 详情页

GPD1L as a potential biomarker associated with Treg cell infiltration and lipid metabolism in clear cell renal cell carcinoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Sichuan Univ, West China Hosp, Natl Clin Res Ctr Geriatr, Lab Aging & Geriatr Med,State Key Lab Biotherapy, Chengdu, Peoples R China [2]Sichuan Univ, West China Hosp, Natl Clin Res Ctr Geriatr, Dept Neurol,Lab Neurodegenerat Disorders, Chengdu, Peoples R China [3]Sichuan Univ, West China Hosp, Rehabil Med Ctr, Chengdu, Peoples R China [4]Sichuan Univ, West China Hosp, Rehabil Key Lab Sichuan Prov, Chengdu, Peoples R China [5]Sichuan Univ, West China Sch Pharm, Chengdu, Peoples R China [6]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Hlth Management, Chengdu, Peoples R China [7]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Inst Hlth Management, Chengdu, Peoples R China
出处:
ISSN:

关键词: CcRCC Immune infiltration GPD1L Treg Lipid metabolism Biomarker

摘要:
Background Clear cell renal cell carcinoma (ccRCC) is a prevalent tumor in the urinary system, presenting a poor prognosis yet being accompanied by a high degree of immune infiltration. Understanding the mechanisms underlying this abnormal infiltration and identifying prognostic biomarkers in this regard is crucial for improving therapeutic outcomes. Methods The expression of GPD1L in ccRCC was analyzed using a common database (TCGA). The expression of GPD1L in ccRCC cell lines and tissue samples was verified by western blotting, real time qPCR and immunohistochemistry. The predictive value of GPD1L was evaluated by survival analysis, ROC curve and Cox regression analysis. We used GO, KEGG and gene set enrichment analysis (GSEA) to verify each other. Then the single cell sequencing dataset (GEO) was further analyzed and verified, and the functional phenotype of GPD1L in ccRCC was explored by functional experiments. In addition, the correlation between the expression level of GPD1L and drug resistance of AKT-mTOR pathway was analyzed based on Genomics of Drug Sensitivity in Cancer database (GDSC). Results We identified glycerol-3-phosphate dehydrogenase 1-like (GPD1L) as a tumor suppressor gene in ccRCC, and downregulation of GPD1L may facilitate the adaptive survival of tumor cells via enhanced regulatory T cells (Tregs) infiltration and lipid metabolism reprogramming in ccRCC. Our results suggest that there is a significantly diminished GPD1L in ccRCC patients with poorer survival probability. Mechanically, a significant negative correlation between GPD1L expression and Tregs infiltration, and GPD1L-related metabolic analysis reflected the correlation between Tregs and lipid metabolism. In addition, GPD1L expression levels also influence the malignant phenotype of ccRCC and the drug resistance to AKT and mTOR targeted therapy. Conclusions Taken together, our results supported GPD1L could be a valuable biomarker for predicting and intervening in ccRCC progression. These insights could shed light on the complex interplay between tumor cell adaptive survival and Treg infiltration, which reflected that the comprehensive and systemic role of GPD1L in ccRCC.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 2 区 医学
小类 | 2 区 医学:研究与实验
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 医学:研究与实验
JCR分区:
出版当年[2024]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2024]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2024版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2024版]

第一作者:
第一作者机构: [1]Sichuan Univ, West China Hosp, Natl Clin Res Ctr Geriatr, Lab Aging & Geriatr Med,State Key Lab Biotherapy, Chengdu, Peoples R China
通讯作者:
通讯机构: [3]Sichuan Univ, West China Hosp, Rehabil Med Ctr, Chengdu, Peoples R China [4]Sichuan Univ, West China Hosp, Rehabil Key Lab Sichuan Prov, Chengdu, Peoples R China [6]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Hlth Management, Chengdu, Peoples R China [7]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Inst Hlth Management, Chengdu, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:65766 今日访问量:2 总访问量:5150 更新日期:2025-12-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号